Kits comprising myokines and platinum-based chemotherapeutic agents for treating colorectal cancer

Patent metadata

Field	Value
Publication number	US-11560414-B2
Application number	US-202016877275-A
Country	US
Kind code	B2
Filing date	May 18, 2020
Priority date	May 16, 2019
Publication date	Jan 24, 2023
Grant date	Jan 24, 2023

Abstract

Disclosed are compositions comprising myokines and their methods of preparation and use. The disclosed myokine compositions and methods may comprise myokines having a molecular weight of greater than about 10 kDa such as myostatin and metrnl. The disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders. In particular, the disclosed myokine compositions and methods may be utilized for treating and/or preventing cell proliferative and metabolic diseases and disorders, such as cancer, and metabolic diseases and disorders, such as diabetes, non-alcoholic fatty liver disease, and heart disease.

First claim

We claim:

1. A kit for treating colorectal cancer, the kit comprising: (a) a first pharmaceutical composition comprising an isolated fraction of myokines comprising an effective amount of one or more myokines for treating colorectal cancer, wherein (i) the one or more myokines have a molecular weight greater than about 10 kDa; and/or (ii) the one or more myokines comprise myostatin, metrnl, or both of myostatin and metrnl; and (b) a second pharmaceutical composition comprising an effective amount of a platinum-based chemotherapeutic agent for treating colorectal cancer.

2. The kit of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for treating a colorectal cancer whose growth is associated with chromatin density.

3. The kit of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for treating a cancer whose growth is associated with epidermal growth factor receptor (EGRF) activity.

4. The kit of claim 1 , wherein the isolated fraction of myokines comprises an effective amount of one or more myokines for inhibiting epidermal growth factor receptor (EGRF) activity.

5. The kit of claim 1 , wherein the kit first pharmaceutical composition comprises myostatin.

6. The kit of claim 1 , wherein the first pharmaceutical composition comprises myostatin and the second pharmaceutical composition comprises oxaliplatin.

7. The kit of claim 1 , wherein the first pharmaceutical composition comprises metrnl.

8. The kit of claim 1 , wherein the first pharmaceutical composition comprises metrnl and the second pharmaceutical composition comprises oxaliplatin.

9. A method for treating colorectal cancer in a subject in need thereof, the method comprising administering to the subject the first pharmaceutical composition and the second pharmaceutical composition of the kit of claim 1 .

Assignees

• Univ Northwestern

Inventors

• Roy Hemant K
• Backman Vadim

Classifications

• A61K31/282 Primary

  Platinum compounds · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/4703

  Inhibitors; Suppressors · CPC title

• C07K14/475 Primary

  Growth factors; Growth regulators · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title